iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Zydus gets USFDA final approval for Sildenafil for Oral Suspension

3 Oct 2022 , 09:17 AM

Zydus Lifesciences Limited informed that the United States Food and Drug Administration (USFDA) has granted final approval to market Sildenafil for Oral Suspension USP 10 mg/ml USRLD: Revatio.
As per the filing, Sildenafil for oral suspension is used to treat high blood pressure in the lungs (pulmonary hypertension). It works by relaxing and widening the blood vessels in lungs which allows the blood to flow more easily.

Decreasing high blood pressure in the lungs allows the heart and lungs to work better and improves ability to exercise. The drug will be manufactured at the group’s formulation manufacturing facility at Baddi, Himachal Pradesh, India.

According to the IQVIA MAT Aug 2022 data, Sildenafil for Oral Suspension had annual sales of USD 65 million in the United States.

Further, the group now has 324 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04.

At around 9:17 AM, Zydus Lifesciences Ltd is currently trading at Rs393.05 per share up by Rs6.35 or 1.64% from its previous closing of Rs386.70 per share on the BSE.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Cadila Healthcare
  • launch
  • news
  • oral solution
  • tablets
  • USFDA approval
  • USFDA nod
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.